PDS Biotechnology Corp Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine Transcript
Greetings. Welcome to PDS Biotechnologies conference call and audio webcast. (Operator Instructions) Please note, this conference is being recorded. I'll now turn the conference over to Nicole Jones with CG Capital. Nicole, you may now begin.
Good morning, and welcome to PDS Biotechnologies conference call and audio webcast. With me today from the company are Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Lauren V. Wood, Chief Medical Officer; and Matt Hill, Chief Financial Officer.
Earlier this morning, PDS Biotech issued a press release announcing its exclusive global license agreement with Merck KGaA, Darmstadt, Germany for M9241, a novel investigational tumor targeting IL-12 compound. We encourage everyone to read the press release as well as PDS Biotech's report on Form 8-K, which will be filed with the SEC shortly.
The company's press release is available on the PDS website at pdsbiotech.com. In addition, this conference call will be archived on the company website for future reference. Before we begin, we need to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |